MarginsXMarginsX
Home › Markets › Health Care › AVIR

Atea Pharmaceuticals Inc. (AVIR)

AVIR trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$4.12
-4.19% on the day
Market cap
$330.9M
Small cap
Revenue · 2021
$351.4M
+622.5% on 2020
Net income · 2021
$121.2M
34.5% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2021-12-31, https://www.sec.gov/Archives/edgar/data/1593899/000095017023005186/0000950170-23-005186-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2021-12-31.

Profile

FieldValue
TickerAVIR on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2020
SEC CIK0001593899
SEC industry codePharmaceutical Preparations
Incorporated inMA

Financials · 2021

LineValue
Revenue$351.4M
Net income$121.2M
Operating income$138.4M
Net margin34.5%
Operating margin39.4%
Revenue growth+622.5%
Cash$764.4M
Total assets$772.9M
P/E (computed)2.7×
P/S (computed)0.9×

Warning signs

Cash runway
8.4 months
$97.9M cash at September 30, 2026
Share count, 1 year
+2.8%
2025-11-10 to 2026-11-06 · -3.8% over 3 years
Going-concern doubt
No
10-Q filed November 9, 2026
Insider net buying, 12 months
$25K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-09
Cash and burn$97.9M cash; operating cash flow -$35.1M a quarter.Report 2026-09-30
Shares outstanding80,304,145 (2026-11-06); 78,126,796 a year earlier; 83,435,513 three years earlier.Cover page 2026-11-06
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorKPMG LLP, Boston, Massachusetts, United StatesPCAOB Form AP 2026-04-01
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $25K, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$32.2M-$28.9M$97.9MNo debt tagsNeeds four quarters10-Q 2026-11-09
Q2 2026
2026-06-30
Not filed-$32.9M-$37.1M$76.5MNo debt tagsNeeds four quarters10-Q 2026-11-09
Q1 2026
2026-03-31
Not filed-$45.4M-$46.4M$79.3MNo debt tagsNeeds four quarters10-Q 2026-11-09
Q4 2025
2025-12-31
Not filed-$44.9M-$28.2M$95.7MNo debt tagsNeeds four quarters10-K 2026-03-05
Q3 2025
2025-09-30
Not filed-$42.0M-$40.4M$77.3MNo debt tagsNeeds four quarters10-Q 2026-11-09
Q2 2025
2025-06-30
Not filed-$37.2M-$32.9M$87.7MNo debt tagsNeeds four quarters10-Q 2026-11-09
Q1 2025
2025-03-31
Not filed-$34.3M-$30.6M$119.4MNo debt tagsNeeds four quarters10-Q 2026-11-09
Q4 2024
2024-12-31
Not filed-$33.5M-$30.4M$64.7MNo debt tagsNeeds four quarters10-K 2026-03-05

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document
FORM S-3
S-32024-11-07
Latest annual report10-K2026-03-05
Latest quarterly / interim10-Q2026-11-09
Latest current report8-K2026-11-09
Latest proxyDEFA14A2026-04-27

Source: SEC EDGAR submissions feed, 318 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-0.2%
1 month-13.7%
3 months-15.2%
Year to date+20.4%
1 year+40.5%
From 52-week high-30.1%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
RZLTRezolute Inc. Common Stock (NV)$3.58-2.05%$346.3M
LRMRLarimar Therapeutics Inc.$3.00-0.66%$311.6M
ENTAEnanta Pharmaceuticals Inc.$10.67-2.91%$310.8M
BNTCBenitec Biopharma Inc.$8.54-5.53%$308.5M
ASPEAspen Neuroscience Inc.$12.23-2.86%$355.6M
GALTGalectin Therapeutics Inc.$3.02-0.98%$305.2M
ALTAltimmune Inc.$1.56-5.17%$303.6M
SPRYARS Pharmaceuticals Inc.$3.59-7.71%$360.9M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier